Phase I study of concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III non-small cell lung cancer

Lung Cancer

Volumn 74, Issue 1, 2011, Pages 69-74

  Cardenal, Felipe ^a   Arnaiz, María Dolores ^a   Morán, Teresa ^b   Jové, Josep ^b   Nadal, Ernest ^a   Porta, Ruth ^c   Solé, Josep María ^a   Brao, Isabel ^a   Palmero, Ramón ^a   Fuentes, Rafael ^c   Núñez, Inmaculada ^d   Caveda, Elena ^d   Cassinello, Alejo ^d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b ICO   (Spain)

^c ICO   (Spain)

^d ELI LILLY AND COMPANY   (Spain)

Author keywords

Cisplatin; Non small cell lung cancer; Pemetrexed; Thoracic radiation

Indexed keywords

CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; PEMETREXED;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHOLANGITIS; CLINICAL ARTICLE; COUGHING; DRUG DOSE ESCALATION; DYSPNEA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HEMOPTYSIS; HUMAN; HYPOXIA; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MICROMETASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; ODYNOPHAGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; CONSOLIDATION CHEMOTHERAPY; DISEASE PROGRESSION; ESOPHAGITIS; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; SURVIVAL ANALYSIS;

EID: 79960845488     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.01.021     Document Type: Article

References (26)

1. Aupérin A., Le Péchoux C., Rolland E., Curran W.J., Furuse K., Fournel P., et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190.
2. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005, 23:5883-5891.
3. Vokes E.E., Herndon J.E., Kelley M.J., Cicchetti M.G., Ramnath N., Neill H., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007, 25:1698-1704.
4. Green M.R., West H., Socinski M.A., Willey J., Daniels L., Lemke K., et al. Impact of the ASCO 2007 presentation of HOG Lun 01-24/USO-023 on the prescribing plans of American medical oncologists for patients with stage IIIB non-small cell lung cancer. J Thorac Oncol 2009, 4:983-987.
5. Chattopadhyay S., Moran R.G., Goldman I.D., Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007, 6:404-417.
6. Pemetrexed, SPC. , accessed June 25, 2010. http://www.ema.europa.eu/humandocs/PDFs/EPAR/alimta/emea-combined-h564es.pdf.
7. Bischof M., Weber K.J., Blatter J., Wannenmacher M., Latz D. Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 2002, 52:1381-1388.
8. Seiwert T.Y., Connell P.P., Mauer A.M., Hoffman P.C., George C.M., Szeto L., et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007, 13:515-522.
9. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
10. Schaake-Koning C., van den Bogaert W., Dalesio O., Festen J., Hoogenhout J., van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992, 326:524-530.
11. Clamon G., Herndon J., Cooper R., Chang A.Y., Rosenman J., Green M.R. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999, 17:4-11.
12. Groen H.J., van der Leest A.H., Fokkema E., Timmer P.R., Nossent G.D., Smit W.J., et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 2004, 15:427-432.
13. Brade A, Bezjak A, Macrae R, Laurie S, Sun A, Cho J, et al. Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010 June 2 (epub ahead of print).
14. Heinzerling J.H., Choy H., Hughes R.S., Govindan R., Bradley J.D., Schwartzberg L.S., et al. Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy for patients with locally advanced non-small cell lung cancer: a phase I trial. J Thorac Oncol 2010, 5:1391-1396.
15. Surmont V., Smit E.F., de Jonge M., Aerts J.G., Nackaerts K., Vernhout R., et al. Pemetrexed and cisplatin with concurrent radiotherapy for locally advanced non-small cell and limited disease small cell lung cancer: results from 2 phase I studies. Lung Cancer 2010, 69:302-306.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
17. Young H., Baum R., Cremerius U., Herholz K., Hoekstra O., Lammertsma A.A., et al. Measurement of clinical and subclinical tumour response using [18F] fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999, 35:1773-1782.
18. Gadgeel S.M., Ruckdeschel J.C., Wozniak A., Patel B., Heilbrun L.K., Chen W., et al. Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients (pts). J Clin Oncol 2008, 26(15 Suppl.). 414s (Abstract 7569).
19. Mornex F., Tourani J.M., Wautot V., Chouaki N., Thareau A., Bourayou N., et al. Pemetrexed and cisplatin in concurrent combination with high dose of thoracic radiotherapy, after induction chemotherapy, in patients with locally advanced non-small cell lung cancer: a phase I study. J Thorac Oncol 2010, 5(15 Suppl.). S73 (abstract 184O).
20. Fournel P., Robinet G., Thomas P., Souquet P.J., Lena H., Vergnenegre A., et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005, 23:5910-5917.
21. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresectable stage III NSCLC: RTOG 94-10. Proc Am Soc Clin Oncol 2003, 22. Abstr 2499.
22. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008, 26:2450-2456.
23. Hanna N., Neubauer M., Yiannoutsos C., McGarry R., Arseneau J., Ansari R., et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5755-5760.
24. Vokes E.E., Herndon J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A., et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002, 20:4191-4198.
25. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
26. Vokes E.E., Senan S., Treat J.A., Iscoe N.A. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009, 10:193-198.